Danaher's imperfect quarter is good enough for us to stay the course
-
最新报道：Danaher reported Q2 revenue of $5.87 billion, slightly below analyst estimates of $5.93 billion, with adjusted EPS of $2.05 beating expectations of $2.03. CEO Rainer Blair acknowledged "imperfections" in the quarter but emphasized the company's strong long-term positioning in biotech and life sciences. The company maintained its full-year guidance, projecting 6% core revenue growth and adjusted EPS of $8.45-$8.60. Investors responded positively, with shares rising 3% in premarket trading, as analysts noted resilience in Danaher's diversified portfolio despite softer demand in some segments. The company highlighted continued strength in its bioprocessing and molecular diagnostics businesses.
下一篇
Nexchain Presale Hits $6.9M as 330% ROI Targets Draw Investors Before August 8 Testnet Launch
- NexChain's presale has raised $6.9M, offering investors a 330% ROI as the project gears up...
24小时热点
热点专题
415697